ALTEOGEN (196170) Q4 2024 earnings summary

Executive summary

• Operates as a biotech company focused on R&D, production, and commercialization of biopharmaceuticals, leveraging proprietary platform technologies for subcutaneous formulations and long-acting biologics.

• Key revenue drivers include licensing deals with global pharma (MSD, Daiichi Sankyo, Sandoz), milestone payments, and product sales.

• 2024 saw the launch of ALT-BB4 (Tergase) and regulatory milestones for biosimilars in major markets.

Financial highlights

• 2024 consolidated revenue: KRW 102.9B, up 6.6% year-over-year.

• Operating income: KRW 25.4B (2023: -KRW 9.7B), net income: KRW 60.7B (2023: -KRW 3.6B).

• Gross margin improved to 62.3% (2023: 32.3%).

• Cash and equivalents at year-end: KRW 19.0B; total assets: KRW 409.0B.

Outlook and guidance

• Expects continued revenue growth from new and existing licensing agreements, product launches, and royalty streams.

• Ongoing clinical and regulatory progress for biosimilars and proprietary biologics in global markets.